Tempus AI, Inc.'s unique data assets and AI-driven oncology solutions make it a promising buy. Click to read more on why the ...

Tempus AI stock is trading at a nosebleed valuation, and despite the compelling long-term upside, it's not worth investing at ...

Aurora Innovation, BYD, and Tempus AI are just three of Lingotto Innovation’s holdings with explosive growth potential.

Baron Funds, an investment management company, released its “Baron Discovery Fund” first quarter 2025 investor letter. A copy ...

We recently published a list of 10 Firms Crushing the Market. In this article, we are going to take a look at where Tempus AI ...

In the assessment of 12-month price targets, analysts unveil insights for Tempus AI, presenting an average target of $64.09, ...

Today, Zacks Investment Ideas feature highlights Palantir PLTR, Tempus AI TEM and Comfort Systems USA FIX. These 3 AI-Relate ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Pathos AI Inc., a startup using artificial intelligence to develop new oncology drugs, today announced that it has raised ...

"By combining internal, pre-clinical experimental data, with real-world data from Tempus on its AI-powered platform, we can profoundly deepen our understanding of cancer biology and accelerate our ...

Tuesday - Analysts at TD Cowen have initiated coverage on Tempus AI Inc (NASDAQ:TEM) stock with a Buy rating and have set a price... On Tuesday, Stifel, a brokerage firm, initiated coverage on ...